Amgen Inc vs. Cardiff Oncology, Inc. Common Stock
Amgen Inc and Cardiff Oncology, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AMGN | CRDF | |
|---|---|---|
| Market Cap | $219.02 billion | $74.71 million |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | — |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | CRDF | |
|---|---|---|
| P/E Ratio | 25.15 | — |
| Price / Book | 18.74 | — |
| Price / Sales | 5.75 | — |
AMGN and CRDF split the valuation factors evenly.
Profitability
| AMGN | CRDF | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | — |
AMGN and CRDF split the profitability factors evenly.
Dividend
| AMGN | CRDF | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 62.61 | — |
AMGN and CRDF split the dividend factors evenly.
Risk & Sentiment
| AMGN | CRDF | |
|---|---|---|
| Short Interest | 1.67% | 1.17% |
CRDF leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, CRDF overview, CRDF financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.